{"doi":"10.1002/hem3.70126","title":"Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma","abstract":"Nivolumab is an anti-PD-1 antibody that is effective in patients with relapsed/refractory (RR) classic Hodgkin lymphoma (cHL). We previously showed PET-adapted sequential nivolumab ± ifosfamide, carboplatin, and etoposide (ICE) chemotherapy as the first salvage in RR cHL was a safe and effective bridge to autologous stem cell transplant (ASCT) (cohort A). We then tested a non-PET-adapted schema where all patients received nivolumab + ICE (cohort B). In this study, we present results from cohort B. Patients with high-risk RR cHL after frontline treatment received 240 mg nivolumab followed by 2-3 cycles of NICE (240 mg nivolumab day 1, standard doses of ICE). High-risk disease was defined as having one of the following: primary refractory cHL, relapse within 1 year of completing frontline therapy, B symptoms at relapse, extranodal disease at relapse, or frontline brentuximab vedotin use. PET/CT was performed after nivolumab × 1 and NICE × 2. Responding patients (complete response [CR] or partial response) were intended to proceed to ASCT. The primary endpoint was CR rate per 2014 Lugano classification. A total of 35 patients were enrolled, all of whom were evaluable for safety and efficacy. Overall response rate and CR were 100% and 86%, respectively; 2-year progression-free survival (PFS) and overall survival (OS) were 88% and 100%, respectively. Thirty-two patients proceeded to ASCT directly after NICE; 2-year post-ASCT PFS and OS were 94% and 100%, respectively. Immune-related toxicities were all grades 1-2, and no patient discontinued treatment for toxicity. Nivolumab/NICE is a highly effective salvage regimen and bridges patients effectively to ASCT.","journal":"HemaSphere","year":2025,"id":514252,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9533,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":436064,"name":"Joycelynne Palmer","orcid":"0000-0001-6480-7557","position":1,"is_corresponding":false},{"id":388069,"name":"Hun Ju Lee","orcid":"0000-0001-7219-5562","position":2,"is_corresponding":false},{"id":1238984,"name":"Iris Isufi","orcid":null,"position":3,"is_corresponding":false},{"id":756937,"name":"Robert Chen","orcid":"0000-0002-2714-2434","position":4,"is_corresponding":false},{"id":389253,"name":"Ni‐Chun Tsai","orcid":null,"position":5,"is_corresponding":false},{"id":401865,"name":"Saro H. Armenian","orcid":"0000-0003-2604-8603","position":6,"is_corresponding":false},{"id":1377470,"name":"James L. Godfrey","orcid":null,"position":7,"is_corresponding":false},{"id":423661,"name":"Joo Y. Song","orcid":"0000-0003-3497-2513","position":8,"is_corresponding":false},{"id":615605,"name":"John H. Baird","orcid":"0000-0001-8291-6546","position":9,"is_corresponding":false},{"id":1241324,"name":"Swetha Kambhampati","orcid":"0000-0002-5776-3274","position":10,"is_corresponding":false},{"id":1110329,"name":"Yazeed Samara","orcid":null,"position":11,"is_corresponding":false},{"id":537471,"name":"Jessica Flores","orcid":null,"position":12,"is_corresponding":false},{"id":871866,"name":"Lacolle Peters","orcid":null,"position":13,"is_corresponding":false},{"id":226996,"name":"Steven T. Rosen","orcid":"0000-0002-8818-7724","position":14,"is_corresponding":false},{"id":400258,"name":"Larry W. Kwak","orcid":"0000-0002-1884-5349","position":15,"is_corresponding":false},{"id":249979,"name":"Stephen J. Forman","orcid":"0000-0002-2803-4152","position":16,"is_corresponding":false},{"id":282395,"name":"Alex F. Herrera","orcid":"0000-0002-9665-7415","position":17,"is_corresponding":false},{"id":387636,"name":"Matthew Mei","orcid":"0000-0002-1109-6955","position":0,"is_corresponding":true}],"reference_count":16,"raw_metadata":null,"created_at":"2026-07-19T02:48:29.165853Z","pmid":"40313510","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}